ECTRIMS: Roche's Ocrevus, given early, cuts wheelchair risk by 42%

Roche is steamrolling with Ocrevus, which has quickly become the top-prescribed drug for new multiple sclerosis patients. And to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.